{"filing":{"accession_number":"0000914475-26-000029","cik":"0000914475","ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"nbix-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/nbix-20260527.htm"},"events":[{"id":8318,"run_id":7303,"accession_number":"0000914475-26-000029","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Neurocrine held its 2026 Annual Meeting of Stockholders on May 27, 2026, with stockholders voting on four matters: election of three Class III Directors (Gorman, Lyons, Mercier), advisory vote on named executive officer compensation, approval of the Amended 2025 Equity Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. All four proposals passed with substantial majorities.","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2163,"accession_number":"0000914475-26-000029","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Item 5.02(e) discloses stockholder approval of an amendment to the Company's 2025 Equity Incentive Plan at the 2026 Annual Meeting. This is a compensatory arrangement disclosure involving equity plan amendments, which directly affects executive and employee compensation structures and is material to investors assessing the registrant's capital allocation and incentive practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:12:28.849358+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2164,"accession_number":"0000914475-26-000029","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Neurocrine's Annual Meeting of Stockholders held on May 27, 2026. The filing presents voting tallies for four matters: election of three Class III Directors (Gorman, Lyons, Mercier), advisory vote on named executive officer compensation, approval of the Amended 2025 Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. All four proposals passed with substantial majorities, and the disclosure includes vote counts (For, Against, Abstentions, Broker Non-votes) for each matter, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:12:28.849358+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2163,"accession_number":"0000914475-26-000029","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Item 5.02(e) discloses stockholder approval of an amendment to the Company's 2025 Equity Incentive Plan at the 2026 Annual Meeting. This is a compensatory arrangement disclosure involving equity plan amendments, which directly affects executive and employee compensation structures and is material to investors assessing the registrant's capital allocation and incentive practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:12:28.849358+00:00","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-05-28"},{"id":2164,"accession_number":"0000914475-26-000029","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Neurocrine's Annual Meeting of Stockholders held on May 27, 2026. The filing presents voting tallies for four matters: election of three Class III Directors (Gorman, Lyons, Mercier), advisory vote on named executive officer compensation, approval of the Amended 2025 Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. All four proposals passed with substantial majorities, and the disclosure includes vote counts (For, Against, Abstentions, Broker Non-votes) for each matter, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:12:28.849358+00:00","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-05-28"}]}